Search Follow us

Addex Therapeutics (ADXN)

Business description

Addex Therapeutics is a Swiss biotech company with a leading position in the identification of allosteric modulators with activity in CNS, inflammatory and metabolic disease. Its pipeline includes two Phase II compounds, with one partnered with J&J.

J&J anxiety go-ahead

Update | Pharmaceutical & healthcare | 06/06/2012

J&J has recently disclosed plans to conduct a Phase II study on the Addex-licensed mGluR2 PAM, JNJ-40411813, in anxiety co-morbid with depression. J&J is concurrently completing its Phase II study of the compound in schizophrenia, with data expected in early/mid Q3. Meanwhile, Addex has cut back its workforce to extend its cash reach while it seeks a partner for dipraglurant, for which positive Phase II data in PD-LID were recently reported.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF32.9m
Last closeCHF2.140
High / Low (52 weeks)CHF2.5 / CHF1.8
Stock market listingSW
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(4.8)(8.9)(23.3)

* % Relative to local index